Published in J Psychiatr Res on October 23, 2012
D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia | NCT01102803
Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry (2014) 1.48
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry (2013) 1.26
D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res (2013) 1.09
D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord (2013) 0.98
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther (2014) 0.92
Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One (2014) 0.90
Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review. Eur J Psychotraumatol (2013) 0.88
Virtual Reality-Enhanced Extinction of Phobias and Post-Traumatic Stress. Neurotherapeutics (2017) 0.82
Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Expert Rev Neurother (2014) 0.82
Exercise Augmentation of Exposure Therapy for PTSD: Rationale and Pilot Efficacy Data. Cogn Behav Ther (2015) 0.82
D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety (2014) 0.80
Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biol Psychiatry (2015) 0.79
Opposing effects of D-cycloserine on fear despite a common extinction duration: interactions between brain regions and behavior. Neurobiol Learn Mem (2013) 0.78
D-cycloserine for treatment of numbing and avoidance in chronic post traumatic stress disorder: A randomized, double blind, clinical trial. J Res Med Sci (2014) 0.78
Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials (2015) 0.76
D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis. PLoS One (2017) 0.75
The effect of D-cycloserine on social anxiety treatment using a behavioral outcome measure and a post-session administration strategy. Behav Anal (Wash D C) (2016) 0.75
G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods (2007) 50.83
Preventing the return of fear in humans using reconsolidation update mechanisms. Nature (2009) 5.82
Mechanisms of fear extinction. Mol Psychiatry (2006) 5.44
Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry (2004) 5.26
Extinction-reconsolidation boundaries: key to persistent attenuation of fear memories. Science (2009) 4.63
Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci (2002) 4.52
The method of minimization for allocation to clinical trials. a review. Control Clin Trials (2002) 4.23
Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry (2008) 3.63
Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry (2006) 3.45
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci (1992) 3.40
Stability of retrieved memory: inverse correlation with trace dominance. Science (2003) 3.27
D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry (2007) 3.03
Memory reconsolidation mediates the strengthening of memories by additional learning. Nat Neurosci (2008) 3.03
Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci (2006) 2.94
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry (2006) 2.77
The labile nature of consolidation theory. Nat Rev Neurosci (2000) 2.58
Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci (2003) 2.39
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry (2008) 2.17
A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry (2012) 2.12
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats. J Neurosci (1998) 1.82
Effectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia. Am J Psychiatry (1995) 1.55
Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem (2005) 1.52
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res (2012) 1.50
Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol (1994) 1.47
A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res (2006) 1.44
A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther (2006) 1.44
The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav Neurosci (1996) 1.33
The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry (2002) 1.28
Selecting a linear mixed model for longitudinal data: repeated measures analysis of variance, covariance pattern model, and growth curve approaches. Psychol Methods (2012) 1.04
D-cycloserine facilitation of fear extinction and exposure-based therapy might rely on lower-level, automatic mechanisms. Biol Psychiatry (2009) 1.04
Cognitive enhancers for anxiety disorders. Pharmacol Biochem Behav (2010) 1.04
IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry (2000) 1.03
Self-directed desensitization for acrophobia. Behav Res Ther (1973) 1.02
The promise of extinction research for the prevention and treatment of anxiety disorders. Biol Psychiatry (2006) 1.00
Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology (1997) 0.93
Cardiac and neuroendocrine responses to exposure therapy in height phobics: desynchrony within the 'physiological response system'. Behav Res Ther (1989) 0.89
Effects of D-cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychother Psychosom (2008) 0.84
Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacol Biochem Behav (1997) 0.81
Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice. Eur J Pharmacol (1994) 0.79
Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med (2007) 8.07
A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry (2008) 6.24
Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry (2006) 3.70
Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2006) 3.66
Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry (2008) 3.64
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry (2003) 3.60
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry (2014) 3.27
A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol (2009) 3.26
Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry (2005) 3.19
Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry (2006) 2.85
Psychological treatments for fibromyalgia: a meta-analysis. Pain (2010) 2.78
Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry (2006) 2.77
Mindfulness-based therapy: a comprehensive meta-analysis. Clin Psychol Rev (2013) 2.75
Prolonged exposure versus dynamic therapy for adolescent PTSD: a pilot randomized controlled trial. J Am Acad Child Adolesc Psychiatry (2010) 2.48
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. Psychother Psychosom (2014) 2.41
The liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther (2002) 2.29
Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med (2004) 2.16
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther (2005) 2.08
Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry (2004) 2.04
Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res (2011) 2.00
Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry (2013) 2.00
Computer-assisted cognitive therapy for depression: maintaining efficacy while reducing therapist time. Am J Psychiatry (2005) 1.97
Effects of suppression and acceptance on emotional responses of individuals with anxiety and mood disorders. Behav Res Ther (2005) 1.97
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry (2013) 1.94
Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol (2012) 1.94
Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf (2009) 1.91
Cross-cultural differences in somatic presentation in patients with generalized anxiety disorder. J Nerv Ment Dis (2006) 1.76
A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety (2008) 1.68
Why Do People Use Facebook? Pers Individ Dif (2011) 1.67
Screening for social anxiety disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depress Anxiety (2009) 1.61
Acceptability and suppression of negative emotion in anxiety and mood disorders. Emotion (2006) 1.58
A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res (2012) 1.50
Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry (2014) 1.48
A meta-analysis of the magnitude of biased attention in depression. Depress Anxiety (2010) 1.47
Reducing anxiety sensitivity with exercise. Depress Anxiety (2008) 1.46
D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning. Neuropsychopharmacology (2010) 1.46
Attending to emotional cues for drug abuse: bridging the gap between clinic and home behaviors. Sci Pract Perspect (2007) 1.44
Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BD. Psychiatr Serv (2005) 1.43
Meta-analysis of the placebo response in antidepressant trials. J Affect Disord (2009) 1.40
Cognitive mechanisms of social anxiety reduction: an examination of specificity and temporality. J Consult Clin Psychol (2006) 1.40
A cross-ethnic comparison of lifetime prevalence rates of anxiety disorders. J Nerv Ment Dis (2010) 1.35
Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev (2008) 1.34
Shared Variance among Self-Report and Behavioral Measures of Distress Intolerance. Cognit Ther Res (2011) 1.33
Prevention of missing data in clinical research studies. Biol Psychiatry (2006) 1.32
Mechanism of change in cognitive-behavioral treatment of panic disorder: evidence for the fear of fear mediational hypothesis. J Consult Clin Psychol (2004) 1.31
Depression and its influence on reproductive endocrine and menstrual cycle markers associated with perimenopause: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry (2003) 1.31
Mediation of changes in anxiety and depression during treatment of social phobia. J Consult Clin Psychol (2005) 1.30
Efficacy of attention bias modification using threat and appetitive stimuli: a meta-analytic review. Behav Ther (2012) 1.29
Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry (2013) 1.29
Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years. Bipolar Disord (2006) 1.28
Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry (2005) 1.28
Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci Ther (2011) 1.27
Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am (2010) 1.26
Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. J Clin Psychiatry (2013) 1.26
Moderators and non-specific predictors of treatment outcome for anxiety disorders: a comparison of cognitive behavioral therapy to acceptance and commitment therapy. J Consult Clin Psychol (2012) 1.26
D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry (2013) 1.26
Does distress tolerance moderate the impact of major life events on psychosocial variables and behaviors important in the management of HIV? Behav Ther (2007) 1.25
Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women's Health Initiative Observational Study. Arch Gen Psychiatry (2007) 1.24
Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev (2007) 1.22
Deficits in emotion-regulation skills predict alcohol use during and after cognitive-behavioral therapy for alcohol dependence. J Consult Clin Psychol (2011) 1.21
Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder. J Consult Clin Psychol (2007) 1.21
Let's get physical: a contemporary review of the anxiolytic effects of exercise for anxiety and its disorders. Depress Anxiety (2013) 1.21
Resilience: research evidence and conceptual considerations for posttraumatic stress disorder. Depress Anxiety (2007) 1.21
Posttraumatic stress disorder symptoms following media exposure to tragic events: impact of 9/11 on children at risk for anxiety disorders. J Anxiety Disord (2007) 1.19
Prefrontal and temporal gray matter density decreases in opiate dependence. Psychopharmacology (Berl) (2005) 1.19
The serotonin transporter gene and risk for alcohol dependence: a meta-analytic review. Drug Alcohol Depend (2010) 1.19
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry (2005) 1.19
Cultural differences in perceived social norms and social anxiety. Behav Res Ther (2005) 1.18
Culture and the anxiety disorders: recommendations for DSM-V. Depress Anxiety (2010) 1.18
A randomized controlled trial of cognitive-behavior therapy for Cambodian refugees with treatment-resistant PTSD and panic attacks: a cross-over design. J Trauma Stress (2005) 1.18
Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord (2002) 1.18
Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry (2005) 1.18